Last reviewed · How we verify
NCT06747026: OCEANUS
Real-World Immuno-Radiotherapy for Advanced NSCLC
trial testing initial Sequential iRT in Lung Cancer Non-Small Cell Cancer (NSCLC) in 338 participants. Completed in 1 December 2024.
1 December 2024
Quick facts
| Lead sponsor | Fengming Kong |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 338 |
| Start date | 1 January 2015 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- initial Sequential iRT — full drug profile →
- initial Concurrent iRT — full drug profile →
- RT with maintenance of ICI — full drug profile →
- RT after discontinuation of ICI — full drug profile →
Conditions studied
- Lung Cancer Non-Small Cell Cancer (NSCLC) — all drugs for Lung Cancer Non-Small Cell Cancer (NSCLC) →
Sponsor
Fengming Kong — full company profile →
Who can join
18 and older, any sex, with Lung Cancer Non-Small Cell Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The optimal combination strategy for radiotherapy combined with immunotherapy (iRT) in advanced non-small-cell lung cancer (NSCLC) remains unclear, and there is a lack of real-world data to validate its efficacy. The objective of this study is to confirm the survival benefits of iRT in advanced NSCLC and to identify the optimal combination strategy for its use.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS-STING pathway: mechanisms, challenges, and combination therapy strategies.
He Y, Zeng X, Liu Q, Zhou L, et al · · 2026 · PMID 41803899 · DOI 10.1186/s12943-026-02634-5 -
The Effect of Myc Inhibition Combined with the Synergistic Effect of Photothermal, Photodynamic and Radiotherapy in Tumor Treatment.
Cui Y, Yang W, Liu W, Li Y, et al · · 2025 · PMID 41103361 · DOI 10.2147/ijn.s526592
Verify or expand the search:
- PubMed search for NCT06747026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer Non-Small Cell Cancer (NSCLC)
Currently open trials in the same condition.
- NCT06810609 — Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC · Phase 2 · recruiting
- NCT06705465 — Cross-sectorial Rehabilitation of Patients with Lung Cancer · NA · recruiting
Other Fengming Kong trials
Trials by the same sponsor.
- NCT06756295 — A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR) · EARLY_PHASE1 · not yet recruiting
- NCT05061342 — Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06747026 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fengming Kong
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06747026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing